165 related articles for article (PubMed ID: 22788843)
1. Novel imidazol-1-ylmethyl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-ones as potent and selective CYP11B1 inhibitors for the treatment of Cushing's syndrome.
Yin L; Lucas S; Maurer F; Kazmaier U; Hu Q; Hartmann RW
J Med Chem; 2012 Jul; 55(14):6629-33. PubMed ID: 22788843
[TBL] [Abstract][Full Text] [Related]
2. Heteroatom insertion into 3,4-dihydro-1H-quinolin-2-ones leads to potent and selective inhibitors of human and rat aldosterone synthase.
Grombein CM; Hu Q; Rau S; Zimmer C; Hartmann RW
Eur J Med Chem; 2015 Jan; 90():788-96. PubMed ID: 25528333
[TBL] [Abstract][Full Text] [Related]
3. Discovery of new 7-substituted-4-imidazolylmethyl coumarins and 4'-substituted-2-imidazolyl acetophenones open analogues as potent and selective inhibitors of steroid-11β-hydroxylase.
Stefanachi A; Hanke N; Pisani L; Leonetti F; Nicolotti O; Catto M; Cellamare S; Hartmann RW; Carotti A
Eur J Med Chem; 2015 Jan; 89():106-14. PubMed ID: 25462231
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase.
Ulmschneider S; Müller-Vieira U; Mitrenga M; Hartmann RW; Oberwinkler-Marchais S; Klein CD; Bureik M; Bernhardt R; Antes I; Lengauer T
J Med Chem; 2005 Mar; 48(6):1796-805. PubMed ID: 15771425
[TBL] [Abstract][Full Text] [Related]
5. N-(Pyridin-3-yl)benzamides as selective inhibitors of human aldosterone synthase (CYP11B2).
Zimmer C; Hafner M; Zender M; Ammann D; Hartmann RW; Vock CA
Bioorg Med Chem Lett; 2011 Jan; 21(1):186-90. PubMed ID: 21129965
[TBL] [Abstract][Full Text] [Related]
6. Selective dual inhibitors of CYP19 and CYP11B2: targeting cardiovascular diseases hiding in the shadow of breast cancer.
Hu Q; Yin L; Hartmann RW
J Med Chem; 2012 Aug; 55(16):7080-9. PubMed ID: 22861193
[TBL] [Abstract][Full Text] [Related]
7. Novel pyridyl substituted 4,5-dihydro-[1,2,4]triazolo[4,3-a]quinolines as potent and selective aldosterone synthase inhibitors with improved in vitro metabolic stability.
Hu Q; Yin L; Ali A; Cooke AJ; Bennett J; Ratcliffe P; Lo MM; Metzger E; Hoyt S; Hartmann RW
J Med Chem; 2015 Mar; 58(5):2530-7. PubMed ID: 25711516
[TBL] [Abstract][Full Text] [Related]
8. Cushing's syndrome: development of highly potent and selective CYP11B1 inhibitors of the (pyridylmethyl)pyridine type.
Emmerich J; Hu Q; Hanke N; Hartmann RW
J Med Chem; 2013 Aug; 56(15):6022-32. PubMed ID: 23869452
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase.
Ulmschneider S; Müller-Vieira U; Klein CD; Antes I; Lengauer T; Hartmann RW
J Med Chem; 2005 Mar; 48(5):1563-75. PubMed ID: 15743198
[TBL] [Abstract][Full Text] [Related]
10. Novel pyridyl- or isoquinolinyl-substituted indolines and indoles as potent and selective aldosterone synthase inhibitors.
Yin L; Hu Q; Emmerich J; Lo MM; Metzger E; Ali A; Hartmann RW
J Med Chem; 2014 Jun; 57(12):5179-89. PubMed ID: 24899257
[TBL] [Abstract][Full Text] [Related]
11. Benzophenones as xanthone-open model CYP11B1 inhibitors potentially useful for promoting wound healing.
Gobbi S; Hu Q; Foschi G; Catanzaro E; Belluti F; Rampa A; Fimognari C; Hartmann RW; Bisi A
Bioorg Chem; 2019 May; 86():401-409. PubMed ID: 30769265
[TBL] [Abstract][Full Text] [Related]
12. Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.
Hu Q; Jagusch C; Hille UE; Haupenthal J; Hartmann RW
J Med Chem; 2010 Aug; 53(15):5749-58. PubMed ID: 20684610
[TBL] [Abstract][Full Text] [Related]
13. A steady state system for in vitro evaluation of steroidogenic pathway dynamics: Application for CYP11B1, CYP11B2 and CYP17 inhibitors.
Mangelis A; Jühlen R; Dieterich P; Peitzsch M; Lenders JWM; Hahner S; Schirbel A; Eisenhofer G
J Steroid Biochem Mol Biol; 2019 Apr; 188():38-47. PubMed ID: 30529282
[TBL] [Abstract][Full Text] [Related]
14. Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis.
Voets M; Antes I; Scherer C; Müller-Vieira U; Biemel K; Barassin C; Marchais-Oberwinkler S; Hartmann RW
J Med Chem; 2005 Oct; 48(21):6632-42. PubMed ID: 16220979
[TBL] [Abstract][Full Text] [Related]
15. Modulation of cytochromes P450 with xanthone-based molecules: from aromatase to aldosterone synthase and steroid 11β-hydroxylase inhibition.
Gobbi S; Hu Q; Negri M; Zimmer C; Belluti F; Rampa A; Hartmann RW; Bisi A
J Med Chem; 2013 Feb; 56(4):1723-9. PubMed ID: 23363058
[TBL] [Abstract][Full Text] [Related]
16. Development of test systems for the discovery of selective human aldosterone synthase (CYP11B2) and 11beta-hydroxylase (CYP11B1) inhibitors. Discovery of a new lead compound for the therapy of congestive heart failure, myocardial fibrosis and hypertension.
Bureik M; Hübel K; Dragan CA; Scher J; Becker H; Lenz N; Bernhardt R
Mol Cell Endocrinol; 2004 Mar; 217(1-2):249-54. PubMed ID: 15134825
[TBL] [Abstract][Full Text] [Related]
17. Fine-tuning the selectivity of aldosterone synthase inhibitors: structure-activity and structure-selectivity insights from studies of heteroaryl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one derivatives.
Lucas S; Negri M; Heim R; Zimmer C; Hartmann RW
J Med Chem; 2011 Apr; 54(7):2307-19. PubMed ID: 21384875
[TBL] [Abstract][Full Text] [Related]
18. Structure-Activity Relationships, Pharmacokinetics, and in Vivo Activity of CYP11B2 and CYP11B1 Inhibitors.
Papillon JP; Adams CM; Hu QY; Lou C; Singh AK; Zhang C; Carvalho J; Rajan S; Amaral A; Beil ME; Fu F; Gangl E; Hu CW; Jeng AY; LaSala D; Liang G; Logman M; Maniara WM; Rigel DF; Smith SA; Ksander GM
J Med Chem; 2015 Jun; 58(11):4749-70. PubMed ID: 25953419
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17)--part II: Core rigidification and influence of substituents at the methylene bridge.
Hu Q; Negri M; Jahn-Hoffmann K; Zhuang Y; Olgen S; Bartels M; Müller-Vieira U; Lauterbach T; Hartmann RW
Bioorg Med Chem; 2008 Aug; 16(16):7715-27. PubMed ID: 18674917
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of 11β-Hydroxylase (CYP11B1) for Treating Diseases Related to Excess Cortisol.
Zhu W; Chen Z; Li Q; Tan G; Hu G
Curr Med Chem; 2016; 23(6):623-33. PubMed ID: 26795197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
